How can molecular biology contribute to the management of congenital adrenal hyperplasia?
The most common form of congenital adrenal hyperplasia is due to a deficiency of 21-hydroxylase (21OHD) activity and is caused by a mutation in the CYP21 gene. By genotyping patients, new and important information can be gained, including presence or absence of 21OHD in borderline cases, determining the severity of disease and identifying heterozygote carriers. Current management of patients with 21OHD involves administering sufficient glucocorticoids to suppress excess adrenal androgen secretion, but not so much that bone growth and mineralization are impaired. New management strategies have been proposed and include administering only substitution doses of corticosteroids and counteracting side-effects by administering an anti-androgen and aromatase inhibitor. Adrenalectomy has also been proposed. Further investigation into these approaches is necessary.
Ritzén
E M
EM
Department of Woman and Child Health, Karolinska Institute, Stockholm, Sweden. martin.ritzen@kbh.ki.se
Lajic
S
S
Wedell
A
A
D000312:Adrenal Hyperplasia, Congenital / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D005260:Female; D005315:Fetal Diseases / Q000188:drug therapy; D006580:Genetic Carrier Screening; D005838:Genotype; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D009154:Mutation; D011247:Pregnancy; D011296:Prenatal Diagnosis; D013255:Steroid 21-Hydroxylase / Q000235:genetics
D005938:Glucocorticoids; D013255:Steroid 21-Hydroxylase